Reaching trans women in San Francisco for efforts to eliminate hepatitis C.
HCV cascade
hepatitis C virus
injection drug use
transgender
Journal
Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
04
02
2021
accepted:
27
03
2021
pubmed:
25
4
2021
medline:
5
10
2021
entrez:
24
4
2021
Statut:
ppublish
Résumé
Hepatitis C infections continue to rise among marginalized communities, including among transgender people. Efforts to eliminate hepatitis C from San Francisco require successful identification of active HCV infections among transgender women and subsequent treatment of infection. This secondary analysis of the National HIV Behavioral Surveillance Transgender Women (NHBS-Trans) Study aims to identify areas of improvement in the hepatitis C care cascade and associated barriers that preclude successful treatment. One hundred and eighty (89.6%) trans women reported being previously screened for HCV, 47 (26.1%) reported being diagnosed with HCV, twenty-eight of the 47 (59.6%) who reported HCV diagnosis also reported that they received HCV treatment, with and 24 of the 28 (85.7%) reported completing their treatment. Overall, we detected HCV antibodies among 23.9% of participants and detected HCV RNA among 6.0%. This suggests that despite improvements in screening for HCV, active cases may not be successfully treated. Efforts to reduce barriers to HCV care should be prioritized, with heightened consideration for trans-specific needs.
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1325-1328Subventions
Organisme : CDC HHS
Pays : United States
Organisme : CDC HHS
Pays : United States
Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Wilson EC, Turner C, Lin J, McFarland W, Burk K, Raymond HF. Hepatitis C seroprevalence and engagement in related care and treatment among trans women. J Viral Hepatitis. 2019;26(7):923-925.
Facente SN, Grebe E, Burk K, et al. Estimated hepatitis C prevalence and key population sizes in San Francisco: A foundation for elimination. PLoS One. 2018;13(4):e0195575. https://doi.org/10.1371/journal.pone.0195575
Grebely J, Prins M, Hellard M, et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis. 2012;12(5):408-414.
Kottilil S. Shortening Treatment for Hepatitis C Virus Infection. Gastroenterol Hepatol (N Y). 2018;14(3):186-188.
Murrell D. Hepatitis C: treatment options for acute and chronic disease. Available from: https://www.healthline.com/health/hepatitis-c/treatment#takeaway
Schillie S. CDC Recommendations for Hepatitis C Screening Among Adults - United States. MMWR Recomm Rep. 2020;69(2):1-17.[Internet]. 2020 [cited 2020 Aug 24];69. Available from: https://www.cdc.gov/mmwr/volumes/69/rr/rr6902a1.htm
Edlin BR, Kresina TF, Raymond DB, et al. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis. 2005;40(s5):S276-S285.
Raymond HF, Wilson EC, McFarland W. Transwoman population size. Am J Public Health. 2017;107(9):e12.